Relevant bibliographies by topics / Non- Hodgkin’s Burkitt lymphoma

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Non- Hodgkin’s Burkitt lymphoma'

Author: Grafiati
Published: 10 January 2023
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non- Hodgkin’s Burkitt lymphoma.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Bencherki, Youssef, Oussama El Idrissi Alami, Amine Moataz, Mohammed Dakir, Adil Debbagh, and Rachid Aboutaieb. "A Case of Primary Burkitt Lymphoma of the Bladder." European Journal of Medical and Health Sciences 3, no. 2 (April 26, 2021): 46–48. http://dx.doi.org/10.24018/ejmed.2021.3.2.798.

Full text
Abstract:
The most frequent primary lymphomas of the bladder are the low-grade B-cell- derived non-Hodgkin’s lymphomas of the MALT type, including Burkitt’s lymphoma. Primary genitourinary localization of lymphomas is uncommon and, in particular supra vesical development of Burkitt lymphoma. The continuous progress of treatment by chemotherapy has changed the pejorative prognosis of this disease into a good one.
APA, Harvard, Vancouver, ISO, and other styles
2

Mugabe Byiringiro, Fiacre, Felix Manirakiza, Déogratias Ruhangaza, Thierry Zawadi Muvunyi, and Belson Rugwizangoga. "Pathology Characteristics of Lymphomas in Rwanda: A Retrospective Study." East African Health Research Journal 5, no. 2 (November 15, 2021): 170–73. http://dx.doi.org/10.24248/eahrj.v5i2.669.

Full text
Abstract:
Background: Lymphomas have been a global challenge for many decades and despite measures for prevention and management, the incidence continues to increase. There are two main categories, which are Non-Hodgkin’s Lymphomas and Hodgkin’s Lymphomas and most common etiologies are environmental, genetic alteration, radiation and some viruses. Objective: To describe pathology characteristics of lymphomas in Rwanda based on Hematoxylin and Eosin stained glass slides and immuno histo chemistry, and classify them according to clinical aggressiveness. Patients and Methods: We conducted a retrospective observational and descriptive study from January 2013 to December 2019. Lymphoma cases were retrieved together with relevant clinical and pathological information, and reviewed by independent pathologists. Histological diagnosis was classified according to the 2008 World Health Organization system in order to assign clinical aggressiveness of the lymphoma. Results: Three hundred and six lymphoma cases were enrolled. Males contributed to 57% of all reviewed case, and slightly over 50% were young aged ≤35 years. Approximately 191 (62%) of cases were nodal lymphomas. Approximately one fifth (18%) of lymphoma cases were HIV positive. Most 213(70%) cases were Non-Hodgkin’s Lymphomas of aggressive forms 164(77%). Among 164 cases of aggressive Non-Hodgkin’s Lymphomas, diffuse large B cell lymphoma was the leading subtype 91(55.5%), followed by solid lymphoblastic lymphoma 32(19.5%) and Burkitt lymphoma 17(10.4%). Among all Hodgkin lymphoma cases, 90(97%) were classical Hodgkin lymphomaof nodular sclerosis subtype. Hodgkin lymphoma patients were younger compared to Non-Hodgkin’s Lymphomas patients (mean age of 24.78±16.3 years versus 38.6±22. 5years, p=.000). Conclusion: Substantial proportion of Lymphomapatients in Rwanda were also HIV positive. Interestingly, Non-Hodgkin’s Lymphomas in Rwanda are predominated by the most aggressive forms, and these mostly affect a younger population. Optimal characterisation of such cases, using advanced methods, is recommended.
APA, Harvard, Vancouver, ISO, and other styles
3

Strauchen, James A., and David Burstein. "Expression of X-Linked Inhibitor of Apoptosis Protein in Reactive Lymphoid Tissues, Non-Hodgkin’s Lymphomas, and Hodgkin’s Disease." Blood 106, no. 11 (November 16, 2005): 4655. http://dx.doi.org/10.1182/blood.v106.11.4655.4655.

Full text
Abstract:
Abstract X-linked inhibitor of apoptosis protein (XIAP) is an important regulator of apoptosis which binds to and inhibits caspases-3, -7 and -9, blocking the caspase 9-mediated apoptosis pathway. This pathway is activated by p53 and DNA damage and may be an important determinant of responsiveness to chemotherapy. Apoptosis also plays a major role in the regulation of follicle center B-cell proliferation and BCL2-mediated inhibition of apoptosis is a key factor in B-cell lymphomagenesis. In this study we examined the expression of XIAP in 65 reactive and neoplastic lymphoid proliferations utilizing a monoclonal antibody to XIAP (#610763 BD Biosciences, San Jose, CA) and immunohistochemistry with avidin-biotin-complex immunoperoxidase technique on formalin-fixed, paraffin-embedded sections. In reactive lymph nodes and tonsils, expression of XIAP was limited to large noncleaved cells in follicle centers (5 of 6 cases). XIAP was absent in plasmacytoma (3 cases) and small lymphocytic lymphoma/chronic lymphocytic leukemia (1 case). XIAP was expressed in follicular lymphoma, predominantly in large noncleaved cells (6 of 9 cases) and in diffuse large B cell lymphoma (11 of 16 cases), including cases of T-cell/histiocyte-rich diffuse large B cell lymphoma (2 cases), primary mediastinal large B cell lymphoma (1 case), and posttransplantation diffuse large B cell lymphoma (1 case). XIAP was consistently expressed in Burkitt and Burkitt-like lymphoma (3 of 3 cases) and anaplastic large cell lymphoma (3 of 3 cases) and in one case of adult T cell leukemia/lymphoma. XIAP was variably expressed in marginal-zone B cell lymphoma, predominantly in large blasts (2 of 4 cases) and in mantle cell lymphoma (2 of 3 cases). XIAP was not detected in peripheral T cell lymphoma, unspecified (1 case), extranodal NK/T cell lymphoma, nasal type (1 case), precursor B cell lymphoblastic leukemia (1 case), or granulocytic sarcoma (1 case). XIAP was consistently expressed in the Reed-Sternberg and mononuclear Reed-Sternberg-variant cells of classical Hodgkin disease (9 of 9 cases) and the L+H Reed-Sternberg-variant cells of nodular lymphocyte predominance Hodgkin disease (3 of 3 cases). XIAP is expressed across a broad range of lymphoproliferative disorders, including classical and nodular lymphocyte predominance Hodgkin disease, diffuse large B cell lymphoma, follicular lymphoma, Burkitt lymphoma, marginal-zone and mantle cell lymphoma, and anaplastic large cell lymphoma. XIAP appears to be selectively expressed in the proliferating elements of these lymphomas. The possible prognostic and therapeutic significance of XIAP expression needs to be determined.
APA, Harvard, Vancouver, ISO, and other styles
4

Mussolin, Lara, Christine Damm-Welk, Marta Pillon, and Wilhelm Woessmann. "Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges." Cancers 13, no. 8 (April 15, 2021): 1907. http://dx.doi.org/10.3390/cancers13081907.

Full text
Abstract:
Minimal residual disease (MRD) detection is established routine practice for treatment stratification in leukemia and used for treatment optimization in adult lymphomas. Minimal disease studies in childhood non-Hodgkin lymphomas are challenged by stratified treatment in different subtypes, high cure rates, low patient numbers, limited initial tumor material, and early progression. Current clinical applications differ between the subtypes. A prognostic value of minimal disseminated disease (MDD) could not yet be clearly established for lymphoblastic lymphoma using flow cytometry and PCR-based methods for T-cell receptor (TCR) or immunoglobulin (IG) rearrangements. MYC–IGH fusion sequences or IG rearrangements enable minimal disease detection in Burkitt lymphoma and -leukemia. An additional prognostic value of MDD in Burkitt lymphoma and early MRD in Burkitt leukemia is implicated by single studies with risk-adapted therapy. MDD and MRD determined by PCR for ALK-fusion transcripts are independent prognostic parameters for patients with ALK-positive anaplastic large cell lymphoma (ALCL). They are introduced in routine clinical practice and used for patient stratification in clinical studies. Early MRD might serve as an endpoint for clinical trials and for guiding individual therapy. Validation of MDD and MRD as prognostic parameters is required for all subtypes but ALCL. Next-generation sequencing-based methods may provide new options and applications for minimal disease evaluation in childhood lymphomas.
APA, Harvard, Vancouver, ISO, and other styles
5

Rathee, Neeraj Kumar, Nidhi Gupta, Sawant Sharma, and Hari Krishan Rathee. "Non-Hodgkin’s Lymphoma Breast in a lactating mother : Case Report." Nepal Journal of Epidemiology 12, no. 1 (March 31, 2022): 1163–70. http://dx.doi.org/10.3126/nje.v12i1.42975.

Full text
Abstract:
Non-Hodgkin’s lymphoma of breast is a rare condition. NHL breast constitute about 0.5% of all malignancies of breast. NHL breast constitute nearly 1% of all cases of NHL. Among all subtypes of NHL, DLBCL (Diffuse large B-cell Lymphoma) is the most common type to be known. Marginal zone lymphoma (10-30%), follicular lymphoma (10-20%) and Burkit Lymphoma (5%) are other common histologic variants. Burkitt lymphoma is mainly seen in pregnant females or lactating females. Breast implant associated anapaestic large cell lymphoma (BIA-ALCL) constitutes remaining case. Thus, primary NHL of Breast is rare condition. DLBCL is most common histologic variant. We report here a rare case of primary NHL Breast. A 30 years old lactating mother came with history of swelling and nipple discharge from bilateral breast. -Treatment approach for low grade NHL breast is Radiotherapy only and for high grade NHL breast there is a role for combined modality approach that is chemotherapy followed by Radiotherapy with or without surgical intervention.
APA, Harvard, Vancouver, ISO, and other styles
6

Munira, Shirajam, Salama Afroze, Akhil Ranjon Biswas, and MA Khan. "Pattern of Immunophenotype Among the Cases of Lymphoma Attending in A Tertiary Level Hospital." Chattagram Maa-O-Shishu Hospital Medical College Journal 17, no. 2 (January 14, 2019): 21–25. http://dx.doi.org/10.3329/cmoshmcj.v17i2.39771.

Full text
Abstract:
Background : To explore the relative frequency and different forms of lymphoma in tertiary level hospital. Methods: This descriptive observational study was carried out in the Department of Hematology at Dhaka Medical College Hospital, Dhaka. Patients attended with solid tissue lymphoma in Outpatient, Inpatient and Lymphoma Clinic services of Department of Hematology and Bone Marrow Transplant, Dhaka Medical College Hospital, Dhaka were taken as study population as per inclusion criteria. A total of 63 patients with lymphoma diagnosed by histopathologically were selected initially, among them 53 were confirmed by immunohistochemistry taken as study population finally. Results: Mean age was 39.2 ± 15.5 years, median age was 36 years within the range of 14 – 75 years. Males were predominant. Male female ratio was 4.3:1. Most of the samples were collected from cervical lymph node (84.1%). Most of the patients came with fatigue and significant weight loss. Maximum 42 (79.24%) cases were Non-Hodgkin’s lymphoma and 11 (20.75%) cases were Hodgkin’s lymphoma. Out of 42 non-Hodgkin’s lymphoma, 27 (64.3%) were B-cell lymphoma and 15 (35.7%) were T-cell lymphoma. Among B-cell lymphoma, 19 (45.2%) were diffuse large B cell lymphoma, three (7.1%) were follicular lymphoma, three (7.1%) were mantle cell lymphoma, one (2.4%) was spleenic marginal zone lymphoma and one (2.4%) was Burkitt lymphoma. Among T-cell lymphoma, nine (21.4%) were peripheral T-cell lymphoma and six (14.3%) were adult T lymphoblastic lymphoma. Out of 11 Hodgkin’s lymphoma, 10 (90.9%) were classical Hodgkin’s lymphoma and one (9.1%) nodular lymphocyte predominant. Among classical Hodgkin’s lymphoma, five (45.5%) were mixed cellularity, three (27.3%) were lymphocyte predominant and two (18.2%) were Nodular sclerosis. Out of 42 non-Hodgkin’s lymphoma, 13 (30.95%) were indolent, 21 (50.00%) were aggressive and eight (19.05%) were very aggressive. Conclusion: In our study, it was found that 79.3% were non-Hodgkin lymphoma of which 64.3% were B-cell lymphoma & 35.7% were T-cell lymphoma and 20.7% cases were Hodgkin lymphoma of which 90.9% were classical Hodgkin’s lymphoma, 9.1% nodular lymphocyte predominant Hodgkin’s lymphoma. Chatt Maa Shi Hosp Med Coll J; Vol.17 (2); Jul 2018; Page 21-25
APA, Harvard, Vancouver, ISO, and other styles
7

Beltran, Brady, Domingo Morales, Pilar Quiñones, R. Salas, and Antonio A. Carrasco-Yalan. "Distribution and Pathology Characteristics of Non Hodgkin Lymphoma in Peru: A Study of 1014 Cases Using WHO Classification of Lymphoid Neoplasm." Blood 110, no. 11 (November 16, 2007): 4419. http://dx.doi.org/10.1182/blood.v110.11.4419.4419.

Full text
Abstract:
Abstract BACKGROUND: The frequency of various subtypes of non-Hodgkin’s lymphoma (NHL) differs in various regions worldwide. OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin’s lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms. METHODS: According to the new WHO classification, a total of 1014 cases of non-Hodgkin’s lymphoma diagnosed during the period 2002–2006 were reviewed and reappraised with their morphological, immunological and clinical characteristics in one general hospital from Lima, Peru. All cases corresponded >18 years old. RESULTS: There were 535 males and 479 females, mean age was 62.1 years (range 18 – 97 years) and the median was 64 years. B-cell neoplasms accounted for 763 cases (75.2%) and T/NK-cell neoplasms for 189 (18.6%). Sixty two cases (6.1%) were not classified. It was seen compared to that in the other Asian countries. Indolent lymphomas accounted for 17%, and aggressive ones for 83%. Among indolent lymphomas follicular grade I and II were the most common subset while MALT was second with low frequency. Among the aggressive lymphomas diffuse large cell lymphoma (DLCL) was the most common subtype, and accounted for 58.8% of all B cell lymphomas. Mantle and Burkitt lymphoma were very low incidence. Among the T cell lymphomas, peripheral T cell lymphomas, mycosis fungoides, Adult T Lymphoma/Leukemia (ATLL), T/NK nasal type Lymphoma were the most common subtypes. Nodal NHL occurred in 52% and extranodal in 48% of the cases. The more common extranodal presentation was stomach (14.1%), skin (8.1%), small intestine (2.9%) and nose (2.3%) CONCLUSIONS: The high incidence of T cell lymphomas, extranodal presentation and reduced frequency of indolent lymphoma in the current study is comparable to that reported from Asian countries.
APA, Harvard, Vancouver, ISO, and other styles
8

Iványi, János László, Éva Marton, Márk Plander, Zoltán Vendel Engert, and Csaba Tóth. "Treatment outcome of primary testicular non-Hodgkin’s lymphoma." Orvosi Hetilap 154, no. 42 (October 2013): 1666–73. http://dx.doi.org/10.1556/oh.2013.29726.

Full text
Abstract:
Introduction: Primary testicular lymphoma constitutes a rare subgroup among extranodal non-Hodgkin’s lymphomas. Because of its aggressive clinical behaviour due to high grade histological features developing mainly in older population, patients with this disease usually have a poor prognosis. Orchidectomy followed by combination immunochemotherapy is a traditional treatment method with a rather inferior outcome. Aim: In this retrospective survey the authors analysed the clinical presentation, pathological features and treatment results of patients with primary testicular lymphoma diagnosed and treated in their haematology centre between 2000–2012 Method: During this period 334 patients with aggressive non-Hodgkin’s lymphomas were treated, of whom 8 patients (2.39%; age between 23 and 86 years; median, 60 years) underwent semicastration for primary testicular lymphoma (7 patients had diffuse, large B-cell lymphoma and one patient had Burkitt-like lymphoma). According to the Ann Arbor staging system a limited stage I-IIE was diagnosed in 7 patients and advanced stage was found in one patient. All but one patients were treated with rituximab added to CHOP regimen (6 or 8 cycles in every 21 or 28 days), whereas one patient received radiotherapy only. Central nervous system intrathecal prophylaxis was used in one case and no preventive irradiation of the contralateral testis was used. Results: With a median follow-up of 50 months complete remission was observed in 7 patients. However, two patients died (one due to progression and one in remission from pulmonary solid tumour). Complete remission rate proved to be 87.5%, disease-free survival was between 13 and 152 months (median 38 months) and overall survival rates were between 17 and 156 months (median 43 months). The 5-year disease-free and overall survival rates were 37.5 %. Conclusions: The relatively favourable treatment outcome could be mainly explained by the high number of patients with early-stage of the disease, early surgical removal of testicular lymphomas and the use if immunochemotherapy. This therapeutic regimen was effective to prevent localized and distant relapses. Despite omission of regular prophylaxis of the central nervous system, no relapse was detected. Orv. Hetil., 154 (42), 1666–1673.
APA, Harvard, Vancouver, ISO, and other styles
9

Cooper, K., A. Gangadharan, R. S. Arora, R. Shukla, and B. Pizer. "Burkitt Lymphoma of Thyroid Gland in an Adolescent." Case Reports in Pediatrics 2014 (2014): 1–3. http://dx.doi.org/10.1155/2014/187467.

Full text
Abstract:
Burkitt Lymphoma is a highly aggressive form of non-Hodgkin’s lymphoma that in nonendemic areas has abdominal primary sites. We report a very rare case of Burkitt lymphoma of the thyroid gland presenting as a rapidly growing thyroid swelling in a 14-year-old white Caucasian British male with no preexisting thyroid or medical problems. The diagnosis was confirmed by an open wedge biopsy following a fine needle aspiration. The patient was treated according to the Children’s Cancer and Leukaemia Group guidelines for BL—Group B protocol and currently is in remission.
APA, Harvard, Vancouver, ISO, and other styles
10

Thandra, Krishna C., Adam Barsouk, Kalyan Saginala, Sandeep Anand Padala, Alexander Barsouk, and Prashanth Rawla. "Epidemiology of Non-Hodgkin’s Lymphoma." Medical Sciences 9, no. 1 (January 30, 2021): 5. http://dx.doi.org/10.3390/medsci9010005.

Full text
Abstract:
Non-Hodgins’s lymphoma (NHL) is the most common hematological malignancy worldwide, accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most prevalent cancer and has the sixth highest mortality among cancers in the US. NHL accounts for 4% of US cancer diagnoses, and incidence has increased 168% since 1975 (while survival has improved 158%). NHL is more common among men, those >65 years old, and those with autoimmune disease or a family history of hematological malignancies. NHL is a heterogenous disease, with each subtype associated with different risk factors. Marginal zone lymphoma (MZL) is strongly associated with Sjogren’s syndrome (SS) and Hashimoto’s thyroiditis, while peripheral T-cell lymphoma (PTCL) is most associated with celiac disease. Occupational exposures among farm workers or painters increases the risk of most of the common subtypes. Prior radiation treatment, obesity, and smoking are most highly associated with diffuse large B-cell lymphoma (DLBCL), while breast implants have been rarely associated with anaplastic large cell lymphoma (ALCL). Infection with Epstein–Barr Virus (EBV) is strongly associated with endemic Burkitts lymphoma. HIV and human herpes virus 8 (HHV-8), is predisposed to several subtypes of DLBCL, and human T-cell lymphoma virus (HTLV-1) is a causative agent of T-cell lymphomas. Obesity and vitamin D deficiency worsen NHL survival. Atopic diseases and alcohol consumption seem to be protective against NHL.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Kriel, Magdalena. "Clinical-pathological characterisation of children with B-cell non-Hodgkin lymphoma over a ten year period at a tertiary centre in Cape Town." Master's thesis, Faculty of Health Sciences, 2020. http://hdl.handle.net/11427/32711.

Full text
Abstract:
Background: We characterized B-cell non-Hodgkin lymphoma (NHL) cases over ten years at a tertiary children's hospital to contribute to the body of knowledge on pediatric lymphoma in developing countries with a high human immunodeficiency virus (HIV) burden. Methods: A retrospective cohort study using clinical and laboratory records of children newly diagnosed with B-cell NHL from January 2005 to December 2014. Results: Seventy-five children ≤ 15 years were included. The majority had Burkitt lymphoma (n = 61). Twenty-five percent (n = 19) were HIV positive and 16% (n = 12) had concurrent active tuberculosis. Bulky disease was present in 65.7% (n = 46) and 30.1% (n = 22) were classified as Lymphomes Malins B (LMB) risk group C. The five year survival estimates for HIV-negative and HIV-positive children were similar in our cohort: 81% vs. 79% for eventfree survival and 85% vs. 83.9% for overall survival. Of three children with Burkitt lymphoma, HIV and LMB group C, two died within one year. Conclusions: Irrespective of HIV status, the survival of children in our B-cell NHL cohort compares favorably with cure rates in developed nations, although advanced disease remains associated with a poor prognosis. Characterization of childhood NHL cases contributes to accurate risk stratification and tailored treatment.
APA, Harvard, Vancouver, ISO, and other styles
2

Guenat, David. "Etude de la prédisposition génétique au cancer dans le syndrome de Williams-Beuren." Thesis, Besançon, 2015. http://www.theses.fr/2015BESA3008.

Full text
Abstract:
Le syndrome de Williams-Beuren (SWB} est une maladie génétique rare causée par une microdélétion de la région 7q11.23. A la suite de l'observation clinique d'une jeune fille atteinte du SWB ayant développé un lymphome de Burkitt à l'âge de 7 ans, nous nous sommes intéressé au lien génétique entre SWB et cancer. L'étude d'une série de cas de cancers survenus chez des enfants atteints de SWB a montré que les lymphomes non-hodgkiniens de type B étaient surreprésentés dans cette population puisque 73% des cancers chez les enfants atteints du SWB étaient des LNH-B. La région critique du SWB a été explorée par CGH-array et séquencage haut-débit dans les échantillons sains et tumoraux de 2 patients atteints de SWB. Aucune perte d'hétérozygotie de la région 7q11.23 n'a été trouvé. En outre, une délétion somatique de la région 7q11.23 a été identifiée dans un lymphome de Burkitt sporadique (Guenat D et al., J Hematol Oncol, 2014). Nous avons ensuite exploré les mécanismes de réponses aux dommages à l'ADN dans des lignées de fibroblastes primaires dérivées de patients atteints du SWB ainsi que dans des lignées 293T traitées avec des siRNA ciblant RFC2, BAZ1B et GTF2/, 3 gènes localisés en 7q11.23 et codant des protéines de réparation de l'ADN. Les cellules dérivées de patients SWB ont montré un défaut de signalisation dans les voies ATM/ATR-dépendantes en réponse aux dommages à l'ADN (Guenat D et al., DNA repair, article soumis). L'haploinsuffisance de la région 7q11.23 associée au SWB pourrait donc jouer un rôle dans la lymphomagenèse B par l'altération de voies de réponse aux dommages à l'ADN ATM/ATR-dépendantes. Cependant, ces résultats mériteraient d'être confirmés dans des modèles murins reproduisant le génotype complet du SWB. Enfin, des données épidémiologiques exhaustives sur l'incidence des pathologies tumorales chez les individus atteints du SWB sont indispensables pour affirmer qu'une prédisposition au cancer existe chez ces patients
Williams-Beuren syndrome (WBS) is a genetic disorder caused by a microdeletion at 7q11.23. The case of a young girl with WBS who developed a Burkitt lymphoma at the age of 7 leads us to explore the genetic link between WBS and cancer. The study of a series of cancers occurred in WBS patients during childhood have shown that B-cell non hodgkin lymphoma are over-represented in this population since 73% cancer cases in WBS were B-NHL. The critical region of WBS was explored by array-CGH and high-throughput sequencing in normal and tumor samples from WBS patients. No loss of heterozygosity at 7q11.23 was found. ln addition, a somatic deletion at 7q11.23 was observed in a sporadic case of Burkitt lymphoma (Guenat D et al., J Hematol Oncol, 2014). DNA damage response mechanisms were then explored in primary fibroblast cell lines derived from WBS patients as well as in 293T cell line treated with siRNA targeting RFC2, GTF2/ and BAZ1 B, 3 genes mapping at 7q11.23 that encode proteins involved in DNA damage response. WBS patients cell lines have shown a defect in ATM/ ATR-dependent DNA damage response pathways (Guenat D et al., DNA Repair, article submitted). Haploinsufficiency of the 7q11.23 region associated with WBS might play a role in B-cell lymphomagenesis through the alteration of ATM/ATR-dependent DNA damage response pathways. However, these results deserve to be confirmed in mouse models that reproduce the complete genotype of human WBS. Finally, strong epidemiological data would be required to confirm the predisposition to cancer in WBS patients
APA, Harvard, Vancouver, ISO, and other styles
3

Sha, Chulin. "Burkitt lymphoma classification and MYC-associated non-Burkitt lymphoma investigation based on gene expression." Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/9250/.

Full text
Abstract:
Burkitt lymphoma and diffuse large B-cell lymphoma are two closely related types of lymphoma that are managed differently in clinical practice and the accurate diagnosis is a key point in treatment decisions. However based on current criteria combined with morphological, immunophenotypic and genetic characteristics, a significant number of cases exhibit overlapping features where diagnosis and treatment decisions are difficult to make. Especially, the prognosis have been reported significantly unfavourable in a subset of cases that are initially diagnosed as diffuse large B-cell lymphoma but bear MYC gene translocation, which is a defining feature of Burkitt lymphoma however can also be found in other lymphomas. Despite the adverse effect of MYC in aggressive lymphomas other than Burkitt lymphoma, the underlying mechanism and effective treatment is still unclear. Recent technological advances have made it possible to simultaneously investigate an enormous number of bio-molecules, and the scientific fields associated with measuring molecular data in such a high-throughput way are usually called “omics”. For example, genomics assesses thousands of DNA sequences and transcriptomics assays large numbers of transcripts in a single experiment. These techniques together with the rapidly emerging analytical methods in bioinformatics have introduced cancer research into a new era. The growing amount of omics data have significantly influenced the understanding of lymphomas and hold great promise in classifying subtypes, predicting treatment responses that will eventually lead to personalized therapy. Here in this study, we investigate the discrimination of Burkitt lymphoma and diffuse large B-cell lymphoma based on DNA microarray gene expression data, which has contributed most in molecular classification of lymphoma subtypes in the last decade. On the basis of two previous research level gene expression profiling classifiers, we developed a robust classifier that works effectively on different platforms and formalin fixed paraffin-embedded samples commonly used in routine clinic. The validation of the classifier on the samples from clinical patients achieves a high agreement with diagnosis made in a central haematopathology laboratory, and leads to a potential outcome indication in the patients presenting intermediate features. In addition, we explore the role of MYC in the above lymphomas. Our investigation emphasizes the inferior impact of high level MYC mRNA expression on patients’ outcome, and the functional analysis of MYC high expression associated genes show significantly enriched molecular mechanisms of proliferation and metabolic process. Moreover, the gene PRMT5 is found to be highly correlated with MYC expression which opens a possible therapeutic target for the treatment.
APA, Harvard, Vancouver, ISO, and other styles
4

Edwards, Jessi K., John B. Bossaer, Paul O. Lewis, and Ashley Sant. "Peripheral Neuropathy in Non-Hodgkin’s Lymphoma Patients Receiving Vincristine with and Without Aprepitant/Fosaprepitant." Digital Commons @ East Tennessee State University, 2020. https://dc.etsu.edu/etsu-works/7795.

Full text
Abstract:
Background: Peripheral neuropathy is a common treatment-related adverse effect associated with vincristine. Vincristine is a major CYP3A4 substrate and is often administered alongside the neurokinin-1 (NK-1) receptor antagonists, aprepitant or fosaprepitant, which are moderate CYP3A4 inhibitors. This inhibition may result in increased concentrations of vincristine and an increased incidence of toxicity. Objective:The primary objective of this study was to investigate if there is a clinically significant drug interaction between vincristine and aprepitant or fosaprepitant resulting in early-onset peripheral neuropathy. The secondary objective of this study was to investigate the cumulative rate of chemotherapy-induced peripheral neuropathy (CIPN). Methodology:This was a single-centered, retrospective, cohort chart review. Patients receiving vincristine-based chemotherapy between 1 July 2010 through 30 June 2018 were identified and reviewed for concomitant use of aprepitant or fosaprepitant and incidence of neuropathy. Early-onset CIPN was defined as neuropathy onset during the first cycle of chemotherapy. Results:A total of 115 subjects were retrospectively reviewed over the study period, of whom 71 were included in the aprepitant/fosaprepitant group and 44 were included in the group without a NK-1 receptor antagonist. Of the subjects who received aprepitant/fosaprepitant, 26.7% experienced early-onset peripheral neuropathy as compared to 22.7% in the group without a NK-1 receptor antagonist (P = 0.627). Overall, CIPN was higher in the group who received aprepitant/fosaprepitant compared to the group without (56% vs. 36%, P = 0.036). Conclusion:There appears to be an increased risk of CIPN with the concomitant use of vincristine and aprepitant or fosaprepitant.
APA, Harvard, Vancouver, ISO, and other styles
5

Farrington, Caroline Cain. "TARGETED DEGRADATION OF THE MYC ONCOGENE USING PP2AB56ALPHASELECTIVE SMALL MOLECULE MODULATORS OF PROTEINPHOSPHATASE 2A AS A THERAPEUTIC STRATEGY FOR TREATING MYCDRIVENCANCERS." Case Western Reserve University School of Graduate Studies / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=case1579905487094187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sorensen, James. "Therapeutic Efficacy of a Co-Q10 Analogue in Combating Cachexia and Mortality Induced by Gold-Standard Paediatric Chemotherapy Regimens." Thesis, 2020. https://vuir.vu.edu.au/41826/.

Full text
Abstract:
Chemotherapy is an effective first-line treatment against cancer; however, it induces a myriad of serious sequalae, including skeletal muscle dysfunction and wasting (SMDW) and fatigue, which we hypothesise is underpinned by mitochondrial dysfunction. When chemotherapy-induced (CI) SMDW is instigated in childhood, it often endures and manifests over the lifespan resulting in exacerbated morbidity and, in some cases, mortality. Despite much research having investigated individual chemotherapeutic agents and their effect on the skeletal muscle in mice (including our own), these models failed to evaluate the potential interactions between agents in a poly-pharmaceutical regimen, or, the effects of long-term and multi-staged chemotherapy regimens like that used in hospitals world-wide. Therefore, this thesis investigated the impact that gold-standard chemotherapy regimens used to combat the three common childhood cancers: acute lymphoblastic leukaemia (ALL), non- Hodgkin’s Burkitt lymphoma (NHBL) and medulloblastoma, on the skeletal muscle system in healthy juvenile mice and monitored the effects of treatment endured over the lifespan. After establishing pre-clinical animal models for three gold-standard chemotherapy regimens, we showed that, regardless of regimen, eight weeks of treatment to four-week-old mice induced considerable skeletal muscle dysfunction which was characterised by significant muscle weakness, fatigability and, in 2 of the 3 regimens, lean mass loss. Although the age of onset of these sequalae were variable (varying between eight-weeks and 30-weeks of life), mitochondrial dysfunction was evident, identifying a point for therapeutic intervention. As such, we investigated the efficacy of daily Idebenone treatment (a powerful antioxidant and mitochondrial Co-Q10 analogue) against mitochondrial dysfunction and thus CI-SMDW. Idebenone co-therapy greatly improved mitochondrial performance in chemotherapy- treated mice, as well as protecting against lean mass loss and improving overall strength in the more aggressive chemotherapy regimen used against NHBL. Moreover, Idebenone co- therapy was shown to completely abate chemotherapy-induced mortality in the NHBL regimen, reducing mortality from 77% to zero. This thesis shows that childhood chemotherapy, regardless of the aggressiveness of the regimen or the classes of drugs used, induces life-long SMDW which is likely contributed to by mitochondrial dysfunction. The mitochondrial targeting therapeutic, Idebenone, shows promising potential for clinical application against the SMDW sequalae and mortality induced by some regimens, with the potential to improve childhood chemotherapy patient outcomes and survivability.
APA, Harvard, Vancouver, ISO, and other styles
7

Foroutan, B., N. Razavianzadeh, and Diana Anderson. "Overcoming chemoresistance in non-Hodgkin lymphoma preliminary studies of apoptosis and necrosis by p-glycoprotein reversal agents." 2015. http://hdl.handle.net/10454/9345.

Full text
Abstract:
No
The in vitro measurement of drug-induced apoptosis provides a mechanism-based test for the chemosensitivity of tumor cells isolated from a patient or from a specific cell line. The goal of this study was to investigate the effects of p-glycoprotein reversal agents on apoptosis and necrosis in Burkitt lymphoma cells. These effects were determined by microscopic observation and by electrophoretic separation of DNA fragments. We demonstrated induction of apoptosis in Burkitt lymphoma Raji Thymidine Kinase+ (TK+)and TK- cells using different subclasses of p-glycoprotein reversal agents. A low dose of doxorubicin was also used. The selective clonal expansion of mutant lymphocytes is based upon the phenotypic properties of TK-deficient cells. The first phase of the present study involved morphological analyses and DNA degradation on agarose gel electrophoresis. The second phase analyzed DNA damage using the Comet assay and tail moments calculated with Komet imaging software. Electrophoretic separation resulted in a ladder pattern, indicating that the p-glycoprotein reversal agents were able to induce apoptosis and necrosis. The morphological frequency of apoptosis and necrosis in the cells was significantly increased. Most p-glycoprotein reversal agents showed an increase in tail moments in the Comet assay. The results indicate that indomethacin and quercetin may help to overcome chemoresistance in Burkitt’s lymphoma.
APA, Harvard, Vancouver, ISO, and other styles
8

Bertram, Nick. "Retrospektive Analyse von Diagnostik, Klinik und Verlauf bei Patienten mit Vena-cava-superior-Syndrom (obere Einflussstauung)." Doctoral thesis, 2015. http://hdl.handle.net/11858/00-1735-0000-0022-5D98-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Leonard, John P., and Morton Coleman, eds. Hodgkin’s and Non-Hodgkin’s Lymphoma. Boston, MA: Springer US, 2006. http://dx.doi.org/10.1007/978-0-387-29346-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carton, James. Haematopathology. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198759584.003.0015.

Full text
Abstract:
This chapter discusses haematopathology, including iron deficiency anaemia, anaemia of chronic disease, megaloblastic anaemias, hereditary spherocytosis, glucose-6-phosphate dehydrogenase deficiency, thalassaemias, sickle-cell disorders, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), von Willebrand disease, haemophilia, thrombophilia, acute B-lymphoblastic leukaemia, acute myeloid leukaemias, chronic lymphocytic leukaemia (CLL), chronic myelogenous leukaemia, polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF), myelodysplastic syndromes (MDS), follicular lymphoma, diffuse large B-cell lymphoma, Burkitt’s lymphoma (BL), extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), mantle cell lymphoma, classical Hodgkin’s lymphoma (cHL), lymphoplasmacytic lymphoma (LPL), plasma cell myeloma, primary amyloidosis, and mature T-cell non-Hodgkin’s lymphomas.
APA, Harvard, Vancouver, ISO, and other styles
3

Collins, Graham, and Chris Bunch. Lymphoma. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0289.

Full text
Abstract:
Lymphoma is a cancerous disorder characterized by a clonal proliferation of lymphocytes. There are two broad categories: Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, with Hodgkin’s lymphoma defined by the presence of Reed–Sternberg cells on histological examination of affected tissue. Within the non-Hodgkin’s lymphomas, there are the much more common B-cell lymphomas and the uncommon T-cell lymphomas. Within the B-cell non-Hodgkin lymphomas, there are clinically aggressive (high-grade) forms and much more indolent (low-grade) forms. This chapter addresses the causes, diagnosis, and management of Hodgkin’s lymphoma and non-Hodgkin’s lymphoma.
APA, Harvard, Vancouver, ISO, and other styles
4

Oliver, Nora, and Elizabeth Chiao. Malignant Diseases in HIV. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0033.

Full text
Abstract:
Malignancies were one of the earliest recognized manifestations that led to the eventual description of the AIDS epidemic. Kaposi’s sarcoma was one of the first entities described in association with AIDS. Subsequently, intermediate-grade and high-grade non-Hodgkin’s lymphoma, invasive cervical cancer, and primary central nervous system lymphoma were defined by the Centers for Disease Control and Prevention as “AIDS-defining conditions.” Since the advent of combination antiretroviral therapy, several other cancers that are not AIDS-defining have been found to have an increased incidence in patients with HIV. These include, but are not limited to, Hodgkin’s disease and anal, liver, lung, oropharyngeal, colorectal, and renal cancers. They are generally referred to as “non-AIDS-defining cancers.” The increasing longevity of persons living with HIV as well as concurrent modifiable risk factors such as tobacco use may also influence the epidemiology of these malignancies.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Egan, Grace, Sheila Weitzman, and Sarah Alexander. "Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma." In Non-Hodgkin's Lymphoma in Childhood and Adolescence, 167–83. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-11769-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Paulsson, Anna K., and Adam Garsa. "Non-Hodgkin’s Lymphoma." In Handbook of Evidence-Based Radiation Oncology, 757–68. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-62642-0_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chung, Hans T., Stephen L. Shiao, and Naomi R. Schechter. "Non-Hodgkin’s Lymphoma." In Handbook of Evidence-Based Radiation Oncology, 583–92. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-92988-0_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hermanek, P., and L. H. Sobin. "Non-Hodgkin’s Lymphoma." In TNM Classification of Malignant Tumours, 180. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-82982-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Portlock, C. S. "Non-Hodgkin’s Lymphoma." In Hematologic Malignancies, 77–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-82734-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Finiewicz, K. J., and J. E. Ultmann. "Non-Hodgkin’s Lymphoma." In Oncologic Therapies, 453–88. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-97988-0_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Espinoza-Delgado, Igor, and Dan L. Longo. "Non-Hodgkin’s Lymphoma." In Allogeneic Stem Cell Transplantation, 83–99. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-333-0_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Jang, Joanne W., and Andrea K. Ng. "Non-Hodgkin’s Lymphoma." In Decision Making in Radiation Oncology, 747–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16333-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pan, Dorothy, and Carol S. Portlock. "Non-Hodgkin’s Lymphoma." In Current Cancer Therapeutics, 310–22. London: Current Medicine Group, 2001. http://dx.doi.org/10.1007/978-1-4613-1099-0_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Finiewicz, K. J., and K. Van Besien. "Non-Hodgkin’s Lymphoma." In Oncologic Therapies, 295–318. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55780-4_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Kamada, Natalie, Robert Oda, Tiffany Shieh, Melissa Agsalda-Garcia, Tayro Acosta-Maeda, Anupam Misra, So Yung Choi, Eunjung Lim, and Bruce Shiramizu. "Abstract A04: Unique Raman spectroscopic fingerprints of Burkitt non-Hodgkin lymphoma." In Abstracts: AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic; December 3-6, 2017; Atlanta, Georgia. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.pedca17-a04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gardiner, Breeana, Louise Taylor, Gemma Renshaw, Sarah Illingworth, and Graeme OConnor. "16 Feeding practices in paediatric Burkitt’s Non-Hodgkin’s lymphoma with mucositis: a retrospective chart review." In GOSH Conference 2020 – Our People, Our Patients, Our Hospital. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2020. http://dx.doi.org/10.1136/archdischild-2020-gosh.16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Narula, T., A. A. Asif, and S. S. Kosseifi. "Tracheal Relapse of Non Hodgkin’s Lymphoma: A Rare Entity." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2327.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yang, Chun-Yuh, and Shang-Shyue Tsai. "0103 Farming and mortality from non-hodgkin’s lymphoma in taiwan." In Eliminating Occupational Disease: Translating Research into Action, EPICOH 2017, EPICOH 2017, 28–31 August 2017, Edinburgh, UK. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/oemed-2017-104636.78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rana, Seema, and Rajiv Tangri. "Anaplastic large cell lymphoma ALK negative vs. peripheral T cell lymphoma (NOS) - diagnostic dilemma." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685354.

Full text
Abstract:
Middle aged female presented with generalised lymphadenopathy and fever for last one month. Peripheral blood findings were within normal limits. There was no extra nodal involvement. FNAC performed initially from a cervical node suggested possibility of Hodgkin’s lymphoma and a whole node biopsy was performed. Histopathogical examination revealed effaced nodal architecture and a polymorphous population of lymphocytes, plasma cells, neutrophils and scattered large mononuclear cells with prominent nucleolus. An initial panel of CD3, CD20, LCA, CD15, CD30 and PAX5 was performed. The large atypical cells were positive for LCA, CD3 and CD30 with variable positivity for CD15. CD 30 showed Golgi and membranous staining. These large atypical cells were negative for PAX5 and CD20. In view of above findings, Hodgkin’s lymphoma was ruled out and a possibility of Non- Hodgkin’s lymphoma was considered. Further IHC markers were performed which included CD2, CD5, CD7, EMA, Alk, CD10 and KI67. CD5 showed variable positivity. The cells of interest were negative for CD2, CD7, ALK and EMA. Ki 67 index was 70-80%. Overall histological and IHC findings favoured Alk negative Anaplastic large cell lymphoma. Differential diagnosis considered was peripheral T cell lymphoma (NOS). Hodgkin’s lymphoma, peripheral T cell lymphoma (NOS) and anaplastic large cell lymphoma share common histomorphological findings. With careful analysis of Immunohistochemistry, it is easier to categorise Hodgkin’s lymphoma. ALK negative anaplastic large cell lymphoma and peripheral T cell lymphoma (NOS) are difficult to categorise and show overlapping features. We in this case have discussed clinical, histomorphological and IHC pattern of Alk negative Anaplastic large cell lymphoma.
APA, Harvard, Vancouver, ISO, and other styles
6

Ndong, J.-R., G. Roy, A. Pillot-Simon, N. Frery, and Dominique Jeannel. "P090 Suspicion of non-hodgkin’s lymphoma aggregate in a research centre." In Occupational Health: Think Globally, Act Locally, EPICOH 2016, September 4–7, 2016, Barcelona, Spain. BMJ Publishing Group Ltd, 2016. http://dx.doi.org/10.1136/oemed-2016-103951.411.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Henderson, E., S. Jha, S. Taj-Eldin, and V. Pathak. "Concurrent Non-Small Cell Carcinoma and Non-Hodgkin’s Lymphoma Within a Same Lymph Node." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moskalets, O. V. "The incidence of anti-drug antibodies in patients with non-Hodgkin’s lymphoma." In Scientific achievements of the third millennium. SPC "LJournal", 2021. http://dx.doi.org/10.18411/scienceconf-06-2021-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shirinzadeh, Laya. "2022-RA-374-ESGO Primary ovarian non-Hodgkin’s lymphoma: a case report." In ESGO 2022 Congress. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/ijgc-2022-esgo.497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sung, Jung-min, Sang-gil Lee, and Eun-A. Kim. "0406 Analysis of infectious disease prevalence among semiconductor manufacturing workers with non-hodgkin’s lymphoma." In Eliminating Occupational Disease: Translating Research into Action, EPICOH 2017, EPICOH 2017, 28–31 August 2017, Edinburgh, UK. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/oemed-2017-104636.334.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Non- Hodgkin’s Burkitt lymphoma"

1

Rituximab helps cure almost all children with non-Hodgkin’s lymphoma. National Institute for Health Research, December 2020. http://dx.doi.org/10.3310/alert_42831.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non- Hodgkin’s Burkitt lymphoma' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography